Micah Mitchell Sells 48,000 Shares of Myomo, Inc. (NYSEAMERICAN:MYO) Stock

Myomo, Inc. (NYSEAMERICAN:MYO) insider Micah Mitchell sold 48,000 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $5.16, for a total transaction of $247,680.00. Following the completion of the sale, the insider now owns 140,572 shares in the company, valued at approximately $725,351.52. This trade represents a 25.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Myomo Stock Performance

Shares of Myomo stock opened at $5.19 on Friday. The company has a market cap of $157.00 million, a P/E ratio of -22.57 and a beta of 1.68. Myomo, Inc. has a twelve month low of $2.51 and a twelve month high of $7.17.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC bought a new position in Myomo in the third quarter worth approximately $36,000. BNP Paribas Financial Markets bought a new position in Myomo in the fourth quarter worth approximately $64,000. Jane Street Group LLC bought a new position in Myomo in the third quarter worth approximately $65,000. Walleye Capital LLC bought a new position in Myomo in the fourth quarter worth approximately $66,000. Finally, Squarepoint Ops LLC bought a new position in Myomo in the fourth quarter worth approximately $74,000. Institutional investors own 44.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Myomo from $7.50 to $9.50 and gave the stock a “buy” rating in a research note on Wednesday. Craig Hallum upped their target price on shares of Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, March 11th. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Myomo in a research note on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $9.25.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.